The GLP-1 Gold Rush Has a Commercial Problem

Venture capital and a growing number of pharmaceutical companies have convinced themselves they’ve found a safe harbor in GLP-1 obesity drugs. Validated biology. Massive patient population. Proven commercial demand. These are exactly the conditions that encourage investment but should make experienced investors nervous.

The funds and companies pouring into GLP-1 development haven’t eliminated investment risk. They’ve traded less clinical uncertainty for greater commercial risk. And commercial risk, in a market already owned by two deeply entrenched incumbents with decades of manufacturing scale, payer relationships, and physician loyalty, is the harder and longer-lasting problem to solve.

According to Ozmosi, a research firm, there are 39 new GLP-1 drugs in development from 34 companies, with only seven among the top 20 pharmaceutical companies. Every one of them is chasing a market where Novo Nordisk and Eli Lilly have spent decades and tens of billions of dollars building a moat that a regulatory approval simply cannot replicate: brand equity, manufacturing infrastructure, payer contracts, and clinical relationships embedded in the administrative backbone of every major health system in the country.

In the commercial world of biotech, regulatory approval does not guarantee product adoption.

I’ve seen this playbook before

History doesn’t repeat itself, but it rhymes. One instructive parallel isn’t another obesity drug, it's Humira.

When AbbVie’s blockbuster rheumatoid arthritis treatment faced the approaching cliff of biosimilar competition, conventional wisdom predicted rapid market erosion. It didn’t happen — not because the biosimilars were inferior, but because AbbVie executed a textbook incumbent defense. They introduced updated formulations, pursued new indications and patents to extend the franchise, and renegotiated payer contracts to make switching economically unattractive. By the time biosimilars arrived in force, AbbVie had restructured the battlefield on its own terms.

Novo Nordisk and Eli Lilly know the playbook. With nearly 40 challengers now visible on the horizon, they are already building the same defense. They can see what’s coming. They know exactly how to prepare and respond.

The physician access problem

Doctors today operate under crushing patient loads and relentless prior authorization burdens. In that environment, familiarity becomes a competitive advantage. Physicians often settle into a small set of preferred therapies that they know how to prescribe, monitor, and defend to payers. The point isn’t that physicians are resistant to innovation. It’s that incumbents benefit from years of accumulated familiarity, creating a commercial advantage that doesn’t appear in most investment models. A new GLP-1 isn’t simply competing against another molecule. It’s competing against established prescribing habits, physician confidence, and workflow familiarity.

The "differentiated indication" argument doesn't solve the herding problem

Some investors argue the more defensible programs are those pursuing differentiated indications — cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease. These are real and serious conditions where better treatments are genuinely needed. But the incumbents are also expanding indications. Novo Nordisk's cardiovascular data is already in semaglutide's label.

Any payer evaluating a late entrant in these indications is running the same formulary calculation: who got here first, how aggressively are they rebating, and what does it actually cost me to add someone new? Investors may see a new indication as a new market. Payers often see it as the same competitive battle. A better molecule, even one approved for a different indication, may not clear that hurdle.

The consumer floor has already shifted

Ro, Hims & Hers, and a growing ecosystem of direct-to-consumer telehealth platforms are communicating to millions of patients to expect GLP-1 access at a fraction of branded cost. That population isn’t waiting for the next premium entrant. They’re looking for cheaper versions of products that work just as well. Thus the addressable market for a new branded compound three years from now could require lower pricing than three years ago. Investors evaluating late entrants may believe they are reducing risk by backing a validated category. In reality, they are competing for a shrinking share in a highly competitive, price sensitive category.

Where the better bet may be

The funds and companies that look prescient a decade from now will likely be those investing today in drugs with genuine clinical uncertainty — in less crowded markets, where unmet need is real and two pharma giants aren't already contesting the path to commercial success.

That might mean a novel mechanism for a disease with no approved therapy, rather than a fourth entrant into a validated market. Or a smaller, harder-to-treat population with a modest but uncontested market, rather than fighting incumbents for scraps of a massive one. The trade is a lower revenue ceiling for a real shot at owning the category outright.

This is a harder pitch for venture capital and companies chasing the obvious category and last years best new idea. The biggest winners won't be those who avoided uncertainty — they'll be those who identified which uncertainty actually mattered, and bet on it before it was obvious.

That's a harder conversation with an LP or board. But four decades of watching markets teach one lesson: when an opportunity looks obvious and draws a crowd, the returns stop being obvious. The GLP-1 rush is no different. The biology may be proven. The commercial gauntlet is not.